The Centers for Disease Control and Prevention recommends everyone six years and older receive the updated shots.

A third COVID-19 vaccine will be available shortly as Novavax joins Pfizer/BioNTech and Moderna in targeting variants that ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Unlike Pfizer/BioNTech and Moderna, Novavax does not use mRNA technology for its COVID-19 vaccine, instead opting for a ...

The FDA granted Emergency Use Authorization to Novavax's updated COVID-19 vaccine for individuals aged 12 and older. The ...

The FDA says the latest vaccine formulae "closely targets currently circulating variants" to give better protection against ...

Sept. 11, 2024 – Social media platforms lit up minutes after the FDA announced its authorization of the updated Novavax COVID-19 vaccine right before Labor Day weekend. It was the last of three ...

The protein-based shot represents a non-mRNA option for the 2024-2025 season, and follows the agency's recent approvals and ...

The newly approved vaccine targets multiple circulating variants, promising enhanced protection and availability across ...

Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for individuals aged 12 years and older. Following this ...

Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back. The FDA authorization for NVAX's updated COVID-19 ...

Friday, the FDA granted Emergency Use Authorization to Novavax Inc.’s (NASDAQ:NVAX) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in ...